Grzegorz S. Nowakowski, MD

Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center

Articles

Unmet Needs in Treating Relapsed/Refractory FL

January 30th 2024

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

January 23rd 2024

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Choosing CAR T-cells as Third-line and Beyond Therapy for FL

January 23rd 2024

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

January 16th 2024

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Zanubrutinib as Third-Line and Beyond Therapy for FL

January 16th 2024

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Dr Nowakowski on the Use of Emavusertib in Relapsed/Refractory Hematologic Malignancies

January 10th 2024

Grzegorz S. Nowakowski, MD, discusses data from the phase 1/2 TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with hematologic malignancies.

Tazemetostat as Third-line and Beyond Therapy for FL

January 10th 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

January 10th 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

CAR T-cells as Third-line and Beyond Therapy for FL

January 2nd 2024

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Current Treatment Options in Second-line FL

January 2nd 2024

Experts on follicular lymphoma discuss second-line treatment options available for patients.

ASH 2023 Updates on Frontline Therapies in FL

January 2nd 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Current Treatment Options in First-line FL

December 18th 2023

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Role of Bispecifics and Future Promising Treatments in DLBCL

August 11th 2022

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.

The Future of DLBCL Treatment

August 11th 2022

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

Management and Work-up of Patients for Salvage Therapy

August 8th 2022

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

August 8th 2022

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

A Closer Look at CAR T-Cell Therapy Clinical Trial Design

July 28th 2022

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL

July 28th 2022

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Therapeutic Sequencing and Bridging in DLBCL

July 22nd 2022

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.

Treating Patients Who Relapse or Progress on CAR T-Cell Therapy

July 22nd 2022

Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.